Bangladesh Pharmaceuticals & Healthcare Report

Published 31 March 2015

  • 100 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Bangladesh Pharmaceuticals & Healthcare Report

BMI View: The gap in the provision of medical services in Bangladesh provides a strong business opportunity for private healthcare providers to make a foray into the market and establish a first mover advantage. This is further affirmed by the persistent challenges facing the Bangladeshi government in remedying the system's shortcomings including a lack of medical infrastructure, illegal clinics and budgetary constraints.

Headline Expenditure Projections

  • Pharmaceuticals: BDT154.21bn (USD1.99bn) in 2014 to BDT171.31bn (USD2.17bn) in 2015; +11.07% in local currency terms and +9.03% in US dollar terms

  • Healthcare: BDT421.33bn (USD5.43bn) in 2014 to BDT470.33bn (USD5.95bn) in 2015; +11.6% in local currency terms and +9.6% in US dollar terms

Risk/Reward Index: While geographic diversification and investment into the pharmaceutical and healthcare sectors of emerging economies such as Bangladesh may be a favourable strategy for any multinational pharmaceutical company, it is vital that a company recognises both the rewards and risks present in a market. In Q215, Bangladesh stands at 15th position out of the 19 regional markets surveyed. Its overall rating of 43.0 out of 100 remains considerably below the average for the region.

Key Trends And Developments

According to the Bangladesh National Health Accounts (BNHA) released in January 2015, the government's contribution to total healthcare expenditure declined from 27% in 2007 to 23% by 2012.

It was announced in February 2015 that UAE-based pharmaceutical company Julphar (Gulf Pharmaceutical Industries) has acquired a majority stake in Bangladesh-based RAK Pharmaceuticals for AED34.9mn (USD9.5mn). The deal will allow Julphar entry into the Bangladeshi pharmaceutical market, further expanding its presence in Asia and enabling the company to leverage its existing emerging market experience.

In March 2015, Bangladesh-based Incepta Pharmaceuticals has launched a USD10 version of Gilead Sciences' hepatitis C drug

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Business Environment
13
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Pharmaceutical Sales, Historical Data And Forecasts
15
Healthcare Market Forecast
16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts
17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts
17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts
18
Prescription Drug Market Forecast
19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts
20
Patented Drug Market Forecast
21
Table: Patented Drug Market Indicators, Historical Data And Forecasts
22
OTC Medicine Market Forecast
23
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts
24
Generic Medicines Market Forecast
25
Table: Generics Drug Market Indicators, Historical Data And Forecasts
26
Pharmaceutical Trade Forecast
27
Table: Pharmaceutical Trade Data And Forecasts
29
Table: Pharmaceutical Trade Data And Forecasts BDT
30
Other Healthcare Data
31
Key Risks To BMI's Forecast Scenario
33
Macroeconomic Forecasts
34
Economic Analysis
34
Lower Investment, Slower Growth
34
Export Sector To Suffer
35
Service Sector Hit Hard
36
Bright Spots Amid Political Crisis
36
Table: Bangladesh - Economic Activity
37
Industry Risk Reward Ratings
38
Asia Risk/Reward Ratings
38
Bangladesh Risk/Reward Ratings
44
Rewards
44
Risks
44
Market Overview
46
Industry Trends And Developments
47
Epidemiology
47
Healthcare Sector
55
Healthcare Sector Financing
59
Healthcare Infrastructure
60
Table: Hospital And Beds, 2002-2006
61
Table: Public Primary Care Facilities, 1994-2004
61
Table: Medical Personnel by Type, 1995-2006
62
Research & Development
63
Table: Suggestions Made By University Of Dhaka's Faculty Of Pharmacy To Improve Pharmaceutical Research
64
Clinical Trials
65
Regulatory Development
67
Regulatory Regime
67
Table: Steps To Establish A Pharmaceutical Manufacturing Unit And Obtain A Drug Manufacturing Licence
69
Counterfeit Drugs
69
Intellectual Property
70
Pricing & Reimbursement
72
Competitive Landscape
75
Pharmaceutical Industry
75
Domestic Pharmaceutical Industry
76
Foreign Pharmaceutical Industry
77
Contract Manufacturing
77
Foreign Company Developments
79
Local Company Developments
81
Distribution Sector
82
Company Profile
84
Eskayef
84
Square Pharmaceuticals
87
Renata
91
Beximco Pharmaceuticals
94
Sanofi
98
Novartis
100
Demographic Forecast
103
Table: Bangladesh's Population By Age Group, 1990-2020 ('000)
104
Table: Bangladesh's Population By Age Group, 1990-2020 (% of total)
105
Table: Bangladesh's Key Population Ratios, 1990-2020
106
Table: Bangladesh's Rural And Urban Population, 1990-2020
106
Glossary
107
Methodology
109
Pharmaceutical Expenditure Forecast Model
109
Healthcare Expenditure Forecast Model
109
Notes On Methodology
110
Risk/Reward Ratings Methodology
111
Ratings Overview
112
Table: Pharmaceutical Risk/Reward Ratings Indicators
112
Indicator Weightings
113

The Bangladesh Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Bangladesh Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Bangladesh pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Bangladesh, to test other views - a key input for successful budgeting and strategic business planning in the Bangladeshi pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Bangladeshi pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Bangladesh.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc